Top Abstract Purchase Related
Home
>
Node
>
Subnode

Influence of low-molecular weight heparin on urine interleukin-6 in patients with proliferative glomerulonephritis

Zhang, H.; Ji, L.Z.; Dai, Z.W.

Hunan Yi Ke da Xue Xue Bao 26(5): 443-444

2001

ISSN/ISBN: 1000-5625
PMID: 12536495
Document Number: 530931
To explore the influence of low-molecular weight heparin (LMWH) on interleukin-6 (IL-6) in patients with proliferative glomerulonephritis, 24 patients which had been distinctly diagnosed by renal biopsy were randomly divided into a control group (n = 12) and a treatment group (n = 12). In addition to the treatments of the control group, the patients of the treatment group were given with LMWH by hypodermic injection for four weeks. The level of urine IL-6 was detected by radioimmunoassay (RIA). The results were that the level of urine IL-6 was higher in patients than that in healthy persons (n = 24); after the treatment, the level of urine IL-6 was significantly decreased both in the control and treatment group, but it was lower in the treatment group than that in the control group. The effect of LMWH on patients with proliferative glomerulonephritis may be associated with inhibiting the proliferation of mesangial cell and the accumulation of mesangial matrix.

Document emailed within 1 workday
Secure & encrypted payments

Morita, Y.; Makino, H.; Ota, K.; Wada, J.; Shikata, K.; Kashihara, N.; Ikeda, S.; Ogura, T.; Ota, Z. 1994: Effect of heparin and low-molecular-weight heparin on proliferative glomerulonephritis Nihon Jinzo Gakkai Shi 36(7): 832-838
Mätzsch, T.; Bergqvist, D.; Blomquist, P.; Jiborn, H. 1987: Influence of standard heparin or low molecular weight heparin on healing of abdominal wounds and colonic anastomoses in rats Acta Chirurgica Scandinavica 153(10): 593-598
Bello, E.; Reuss, L.; Lazcano, F.; Kahler, R.; Murray, G.; von Stowasser, V.; De los Reyes, M.P. 1973: Treatment of proliferative glomerulonephritis with heparin and dipiridamol Revista Medica de Chile 101(4): 279-285
Petralia, P.; Kakkar, A.K. 2004: Antithrombotic therapy with low molecular weight heparin in cancer patients European Journal of Medical Research 9(3): 119-124
Gilmore, G.; Thom, J.; Baker, R.I. 1996: Diagnosis of APC resistance in patients on standard or low molecular weight heparin Thrombosis and Haemostasis 75(2): 372-373
Huisse, M.G.; Huet, Y.; Zygelman, M.; Guillin, M.C. 1983: Thrombopenia induced by standard heparin. Therapeutic attempt using a low molecular weight heparin Presse Medicale 12(10): 643
Uzan, A.; Marin, J.; Mardiguian, J.; Trillou, M.; Kiosseff, T.; Rougeot, C. 1987: Comparative pharmacokinetic study, in the dog, of low molecular weight heparin and standard heparin by labelling with 35S Annales Pharmaceutiques Francaises 45(6): 429-437
Párama, J.A.; Llorens, R.; Sáenz de Buruaga, J.; Rocha, E. 1994: Low-molecular-weight heparin in a patient with heparin-induced thrombocytopenia and a cardiopulmonary bypass Medicina Clinica 102(16): 637-638
Godoy, I.; Herrera, C.; Zapata, C.; Kunstmann, S.; Abufhele, A.; Corbalán, R. 1998: Comparison of low-molecular-weight heparin and unfractionated heparin in the treatment of unstable angina Revista Medica de Chile 126(3): 259-264
Eriksson, E.; Wollter, I.M.; Christenson, B.; Stigendal, L.; Risberg, B. 1988: Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin Thrombosis and Haemostasis 59(2): 284-288
Bannon, P.G.; Kim, M.J.; Dean, R.T.; Dawes, J. 1995: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin Thrombosis and Haemostasis 73(4): 706-712
Kaiser, B.; Hauptmann, J.; Markwardt, F. 1988: Experimental studies on the antithrombotic and haemorrhagic effects of heparin and a low molecular weight heparin derivative Folia Haematologica 115(1-2): 119-125
Nakagawa, M. 1993: Heparin, low molecular weight heparin, heparinoid, and antithrombin IIi therapy of disseminated intravascular coagulation Nihon Rinsho. Japanese Journal of Clinical Medicine 51(1): 87-92
Lai, S.; Barbano, B.; Cianci, R.; Gigante, A.; Di Donato, D.; Asllanaj, B.; Dimko, M.; Mariotti, A.; Morabito, S.; Pugliese, F. 2010: The risk of bleeding associated with low molecular weight heparin in patients with renal failure Giornale Italiano di Nefrologia: Organo Ufficiale Della Societa Italiana di Nefrologia 27(6): 649-654
Bârzu, T.; Molho, P.; Tobelem, G.; Petitou, M.; Caen, J.P. 1984: Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture Nouvelle Revue Francaise d'Hematologie 26(4): 243-247
Chigot, P.; De Gennes, C.; Samama, M.M. 1996: Osteoporosis induced either by unfractionated heparin or by low molecular weight heparin Journal des Maladies Vasculaires 21(3): 121-125
Hull, R.D.; Raskob, G.E.; Rosenbloom, D.; Pineo, G.F.; Lerner, R.G.; Gafni, A.; Trowbridge, A.A.; Elliott, C.G.; Green, D.; Feinglass, J. 1997: Treatment of proximal vein thrombosis with subcutaneous low-molecular-weight heparin vs intravenous heparin. An economic perspective Archives of Internal Medicine 157(3): 289-294
Gouault-Heilmann, M.; Contant, G.; Pochmalicki, G.; Jan, F. 1984: Disseminated intravascular coagulation induced by heparin. Treatment with a combination of low-molecular weight heparin and concentrated antithrombin IIi Presse Medicale 13(22): 1393-1394
Bacher, P.; Horst, B.; Breyer, H.G.; Hoppensteadt, D.A.; Walenga, J.M.; Fareed, J. 1993: Postoperative monitoring of low molecular weight heparin prophylaxis in high-risk patients Seminars in Thrombosis and Hemostasis 19(Suppl 1): 73-78
Mousa, S.A.; Fareed, J. 2001: Overview: from heparin to low molecular weight heparin: beyond anticoagulation Current Opinion in Investigational Drugs 2(8): 1077-1080